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Abstract: Parasitic diseases are amongst the foremost threats to human health and welfare around the world. In tropical 
and subtropical regions of the world, the consequences of parasitic infections are devastating both in terms of human 
morbidity and mortality. The current available drugs are limited, ineffective, and require long treatment regimens. To 
overcome these limitations, the identification of new macromolecular targets and small-molecule modulators is of utmost 
importance. The advances in genomics and proteomics have prompted drug discovery to move toward more rational 
strategies. The increasing understanding of the fundamental principles of protein-ligand interactions combined with the 
availability of compound libraries has facilitated the identification of promising hits and the generation of high quality 
lead compounds for tropical diseases. This review presents the current progresses and applications of structure-based drug 
design (SBDD) for the discovery of innovative chemotherapy agents for a variety of parasitic diseases, highlighting the 
challenges, limitations, and future perspectives in medicinal chemistry. 
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INTRODUCTION 
 Infectious disease is one of the most serious global 
problems and represents a major socio-economic challenge 
facing humanity [1-4]. In fact, several infectious diseases are 
amongst the top 20 leading causes of deaths in the world [5]. 
They are caused by pathogenic organisms such as bacteria, 
viruses, fungi, or parasites that invade the host for repro-
duction. In developing countries the problem is aggravated 
by the lack of well-established public health policies and the 
failure in the implementation of sanitation programs. Parti-
cularly, this scenario contributes to the spread and preva-
lence of parasitic diseases. 
 The parasitic diseases are also known as tropical diseases 
(or neglected diseases) and include illnesses such as malaria, 
tuberculosis, African trypanosomiasis (sleeping sickness), 
Chagas’ disease, dengue, leishmaniasis, schistosomiasis, 
onchocerciasis and lymphatic filariasis. Endemic in many 
developing countries, it is estimated that they affect about 
one person in six in the world [6-8]. In spite of the alarming 
health, economic, and social consequences of these parasitic 
infections, the limited existing drug therapy suffers from a 
combination of drawbacks including poor efficacy, resis-
tance, and serious side effects [7-9]. Therefore, there is an 
urgent need for new, safe and effective drugs for human use. 
Nevertheless, the low economic profile of the affected 
developing countries is not sufficient to attract investments 
to the discovery and development of new antiparasitic agents 
[9]. Aiming at overcoming this limitation, new approaches to 
strength drug discovery for tropical diseases have been 
fomented. These include the publicly-funded sequencing of  
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the genomes of several parasites and the establishment of 
new public–private partnerships (PPPs) whose focus is spe-
cifically on tropical diseases [7-11].  
 The PPP initiative has been forging a close relationship 
between the public-sector and the pharmaceutical companies. 
Hence, a new scenario of drug discovery for tropical diseases 
has emerged, including important pharmaceutical industries 
such as Pfizer, Sanofi-Aventis, Bayer, Pharmacopeia and 
Merck Serono. The role of these companies in the drug dis-
covery campaign involves: (i) compound supply for testing; 
(ii) high-throughput screening (HTS) assays; (iii) medicinal 
chemistry/pharmacokinetic development and (iv) training. 
Simultaneously, several other large companies, such as 
GlaxoSmithKline, Novartis, AstraZeneca and Eli Lilly, have 
founded research institutes dedicated to research into tropical 
diseases [7,10]. 
 The PPPs are coordinated initiatives structured in line 
with industry management practices and funded by national 
governments and philanthropic institutions. They involve 
multi-disciplinary networks of investigators in a venture 
including industry, public-sector and academia from deve-
loped and developing countries that proved to be cost-
efficient vehicles for clinical-product development [11]. The 
mission of these organizations relies on delivering effica-
cious and affordable drugs to the patients in developing 
countries. In addition, the main goals include: (i) the deve-
lopment of new tools and methodologies for disease diag-
nosis and control; (ii) strength the research capabilities in 
disease-endemic countries and (iii) technology transfer [8]. 
Examples of successful PPPs are the Medicines for Malaria 
Venture (MMV) [12], the Institute for OneWorld Health 
(iOWH) [13], the Global Alliance for Tuberculosis Drug 
Development (GATB) [14], the Drugs for Neglected 
Diseases initiative (DNDi) [15] and the Special Programme 
for Research and Training in Tropical Diseases (TDR) [16], 
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which have favorably contributed to boost the discovery and 
development of novel antiparasititc drugs. 
STRATEGIES FOR DRUG DISCOVERY FOR 
TROPICAL DISEASES  
 Due to the fact that antiparasitic drug discovery is not 
primarily commercial-driven, other approaches to the deve-
lopment of novel drugs have been exploited (Table 1). Many 
drugs currently indicated for the treatment of parasitic 
infections were first developed for other diseases. This 
approach, also known as label extension, has clear advan-
tages, including short term development time and cost redu-
ction. Since the drug was first investigated for other indi-
cation and is already approved for therapy, the medicine 
shows acceptable pharmacokinetics and toxicity profile. In 
contrast, some pharmaceutical companies, aware of the risk 
of unexpected toxic effect, are reluctant in allowing further 
investigation of their drugs for neglected diseases [9,11].  
 A similar approach that relies on already existing 
medicines is drug combinations [9,11,17]. This strategy has 
been very successful and continues to play an important role 
in the drug development paradigm for parasitic diseases 
[18,19]. For instance, drug combination therapy is employed 
for the treatment of sleeping sickness (e.g., eflornithine and 
melarsoprol) [20], schistosomiasis (e.g., praziquantel and 
oxamniquine) [21] and malaria (e.g., sulphadoxine and 
pyrimethamine) [22]. Improved efficacy associated with 
lower cost and toxicity is usually observed in several combi-
nation regimens [17].  
 Although their notably importance for the treatment of 
parasitic infections, combination strategies do not provide 
the opportunity to identify new molecular entities with 
biological activity. Particularly, the discovery of novel anti-
infective compounds is important to overcome current 
treatment limitations (e.g., high cost, drug resistance, loss of 
efficacy, lack of selectivity and poor pharmacokinetic 
profiles) [23-27]. A start point to tackle these issues is the 
molecular manipulation of known drugs or active classes of 
compound to generate new scaffolds with improved potency, 
safety or straightforward synthesis. Currently, analogues of 
existing antiparasitic drugs are under investigation for a 
variety of neglected diseases [28-37]. 
 An alternative approach based on known active com-
pounds classes is the piggy-back discovery [38]. Commonly, 
the strategy is applied when active compounds developed for 
other therapeutical indications are employed as good che-
mical starting points to design new drugs against molecular 
targets from parasites. In this scenario, the lead compounds 
are already developed in terms of medicinal chemistry, phar-
macokinetics, and toxic profile. Nevertheless, further stru-
cture-activity relationships (SAR) investigation is required to 
generate clinical candidates with enhanced biological 
properties towards the pathogenic organism (e.g., selec-
tivity). Notable successes have been achieved with this stra-
tegy, for instance, eflornithine (Ornidyl
®
, Sanofi-Aventis) 
and miltefosine (Impavido
®
, Zentaris) were originally 
developed for cancer and later used for African try-
panosomiasis and visceral leishmaniasis, respectively. Iver-
mectin (Stromectol
®
, Merck), first developed for dog 
heartworm, was subsequently applied for human oncho-
cerciasis. More recently, inhibitors of cysteine protease and 
protein farnesyl transferase, which were identified as 
promising drugs for osteoporosis and cancer [38,39], have 
been investigated for the chemotherapy of malaria and 
trypanosomiasis [38,40].  
Table 1. Antiparasitic Drug Discovery Strategies Features 
Impact Project risk Possibility Limitation Example Indication 
Label extension 
Short-term Low  
Reduction in cost and 
development time 
Companies reluctance of 
risk uncovering toxicities 
Pafuramidine; miltefosine 
Sleeping sickness; 
Leishmaniasis 
Drug combination  
Short-term Low 
Synergy, lower dose, 
reduced toxicity 
Development of resistance Eflornithine- melarsoprol Sleeping sickness 
Piggy-back discovery 
Medium-term Medium 
Quick identification 
of lead series; NCE 
Homologous target has to 
be crucial to parasite 
survival and being 
investigated for other 
commercial indication 
Screening of leads series of 
histone deacetylase; cysteine 
protease; farnesyl transferase  
inhibitors 
Malaria; Sleeping 
sickness; Chaga’s 
disease 
De novo discovery 
Long-term High 
Innovative drugs; new 
targets; novel and 
affordable treatments 
Higher cost; attrition rate 
HTS campaigns; lead 
identification 
Malaria; Sleeping 
sickness; Chagas’  
disease; 
Leishmaniasis 
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 Advances in medicinal chemistry at the interface of 
chemistry and biology have created an important foundation 
in the search for new drug candidates that possess a com-
bination of optimized pharmacodynamic and pharma-
cokinetic properties [41]. In this regard, the most attractive 
strategy for the development of clinically relevant agents for 
the treatment of parasitic diseases is the de novo discovery 
approach [9,11]. It is focused on the identification of new 
chemical entities (NCE), both synthetic compounds and 
natural products, against new validated molecular targets 
from parasites. Owing to its intrinsic innovative nature, de 
novo discovery strategy offers the opportunity to develop 
active substances that match the desired profile for anti-
parasitic drugs, which includes: (i) low cost pharmaceuticals; 
(ii) efficacy against drug-resistant strains; (iii) cure within a 
reasonable time to ensure good compliance; (iv) safety; and 
(v) appropriate formulations for oral administration [17].  
 The strategy involves target-based HTS and medium-
throughput screening (MTS) with in vitro assays against 
biological relevant molecular receptor as well as whole 
parasites. Moreover, sophisticated chemoinformatic metho-
dologies integrated to genomics, in silico screening, and 
structural determination of the targets and their molecular 
complex with small ligands are commonly applied in de 
novo drug discovery. 
 Specific knowledge about ligand binding mode and 
mechanism of action is of great importance to guide the 
design of novel and relevant bioactive molecules. Thus, this 
paper presents an overview of the structure-based drug 
design (SBDD) approaches and recent advances for the 
discovery and development of novel therapeutic agents 
against tropical diseases. 
MOLECULAR TARGETS FOR DRUG DESIGN 
 Several critical and unrelated macromolecules are 
exploited as chemotherapeutic targets. In this regard, bio-
chemical pathways general to parasites but absent from 
mammalian hosts have long been an attractive source of 
molecular targets for anti-infective drug development 
[23,27]. Additionally, biochemical peculiarities of the 
parasites such as (i) turnover rates [42,43]; (ii) structure of 
biological membranes [44-47]; (iii) cell signaling [48] and 
(iv) protein expression and regulation [49] have also been 
investigated as potential targets for drug intervention [50].  
 The knowledge of parasite biology as well as the availa-
bility of the whole genomes and proteomics provides a wide 
range of novel targets for drug design [51-54]. The wealth of 
information generated by these experiments has created the 
need for robust and reliable data processing methods to 
analyze and identify relevant molecular targets. This sce-
nario prompted the development of integrated approaches on 
the basis of the knowledge from different disciplines such as 
chemistry, biology and informatics. In this context, the che-
mogenomics is an attractive and useful strategy to define and 
assess the chemical and biological space [55,56]. In order to 
improve the efficiency of early-stage discovery and speeding 
up the screening process, chemogenomics methods are 
widely applied to assign priority to the most promising mole-
cular receptors for further investigation, thereby enabling 
potential targets to be selected before expensive and time-
consuming drug-screening and optimization studies are 
undertaken [57]. 
 Concomitantly, the evolution of structural biology and 
computational methods has led to the determination of high-
resolution atomic structures of many relevant targets for 
antiparasitic drug discovery projects. The TDR program of 
the World Health Organization supports and manages a 
network of academic and industrial centers that established a 
portfolio of drug targets for tropical diseases using the 
wealth of available genomics and proteomic information 
[58].  
 Structural data of several important drug-metabolizing 
enzymes is now available, which potentially enables the 
structure-based rational optimization of potency, selectivity 
and metabolism. However, the use of these data has not 
delivered the predicted new generation of anti-infective 
drugs yet. To tackle this problem, chemogenomics methods 
applied to pathogenic organism are employed to assign 
priority to targets not only on the biological relevance, but 
also on the basis of their “druggability” profile (i.e., the 
probability that the targets will bind to drug-like molecules) 
[59]. Tables 2 and 3 show several essential parasite proteins 
as molecular targets with available structural information 
and their druggability index.  
SBDD AND TROPICAL DISEASES 
 Structure-based approaches have become essential com-
ponents of modern medicinal chemistry [41]. Over the past 
decade, high-performance computers, algorithms, methods 
and expertise have evolved and transformed SBDD methods 
in tools of large impact in drug discovery [60-62]. They 
incorporate information from the target receptor, hence, 
these knowledge-driven approaches require extensive 
informations about the target topology under investigation 
(e.g., X-ray or NMR structure, or robust homology 
modeling) [63]. In this context, public databases such as the 
Protein Data Bank (PDB) [64], InterPro [65-67], ExPASy 
[68], and Relibase [69-71] are invaluable data sources to 
retrieve and analyze 3D structures of target proteins. 
 The molecular recognition phenomenon relies on 
properties and features of a binding pocket, which are 
determined by the amino acids present in the binding cavity. 
The spatial arrangement of the amino acids within the bin-
ding site specifies structural and physicochemical constraints 
that must be met by any putative ligand. Therefore, a 
detailed analysis of the stereo-electronic properties of the 
target binding pocket provides useful insights into relevant 
ligand-receptor interactions that can be optimized to enhance 
the biological properties of lead compounds [41].  
 The SBBD produced several success stories and has been 
continuously employed as an important tool to assist the 
design of compounds for a variety of diseases and disorders 
[72]. Particularly, investigations on novel anti-infective 
compounds led to the identification and development of 
distinct sets of available drugs, for instance, the anti-HIV 
(e.g., saquinavir - Invirase
®
; ritonavir - Norvir
®
; nelfinavir - 
Viracept
®
) and antiviral (oseltamivir - Tamiflu
®
; zanamivir - 
Relenza
®
) agents.  
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Table 2. Druggability Index and 3D Structure Availability of Essential Drug Targets in Trypanosomatids 
Organism Molecular Target Druggability Index*
 
PDB Code 
farnesyl pyrophosphate synthase 1.0 1YHK; 1YHL; 1YHM 
trypanothione reductase 0.7 1AOG; 1BZL; 1GXF; 1NDA 
glyceraldehyde 3-phosphate dehydrogenase 0.6 1K3T; 1ML3; 1QXS; 3DMT 
cyclophilin 0.6 1XO7 
triosephosphate isomerase 0.6 1CI1; 1SUX; 1TCD 
tryparedoxin peroxidase - 1UUL 
cruzain - 
1AIM; 1EWL; 1EWM; 1EWO    1EWP; 1F29; 
1F2A; 1F2B; 1F2C; 1ME3; 1ME4; 2AIM    
T. cruzi 
tyrosine aminotransferase - 1BW0 
triosephosphate isomerase 0.8 1AMK; 1IF2; 1N55; 1QDS 
glyceraldehyde 3-phosphate dehydrogenase 0.8 1A7K; 1GYP; 1GYQ; 1I32; 1I33 
pteridine reductase 1 0.7 1E7W; 1E92; 1P33; 1W0C    
cyclophilin 0.6 2HAQ 
cysteine peptidase C 0.6 1BF7 
cyclophilin a 0.6 2HAQ 
glucose-6-phosphate isomerase 0.2 1Q50; 1T10 
fructose-1,6-bisphosphate aldolase 0.2 1EPX 
adenine phosphoribosyltransferase 0.2 1MZV; 1QB7; 1QB8; 1QCC; 1QCD 
pyruvate kinase 0.2 1PKL 
coproporphyrinogen iii oxidase 0.2 1VJU 
glycerol-3-phosphate dehydrogenase 0.2 1EVY; 1EVZ; 1JDJ; 1M66; 1M67; 1N1E; 1N1G 
L. major 
transketolase - 1R9J 
prostaglandin f synthase 0.8 1VBJ 
phosphoglycerate kinase 0.8 13PK; 16PK 
glyceraldehyde 3-phosphate dehydrogenase, 0.8 1GGA 
farnesyl pyrophosphate synthase 0.8 2EWG; 2I19 
triosephosphate isomerase 0.6 
1AG1; 1DKW; 1IIG; 1IIH; 1KV5; 1ML1; 1MSS; 
1MTM; 1TPD; 1TPE; 1TPF; 1TRD; 1TRI; 1TSI; 
1TTI; 1TTJ; 3TIM; 4TIM; 5TIM; 6TIM 
6-phosphogluconate dehydrogenase 0.25 1PGJ 
tryparedoxin - 1O73 
fructose-bisphosphate aldolase - 1F2J 
T. brucei 
enolase - 1OEP 
*The druggability index values range from 0 to 1, where a larger index score means a more likely to be druggable target. The druggability index is a composite score consisting of a 
weighted normalised sum, where each of the different druggability prediction methods are given different weights depending on their relative contribution to prediction [58].  
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Table 3. Druggability Index and 3D Structure Availability of Essential Drug Targets in Plasmodium Falciparum 
Organism Molecular Target Druggability Index*
 
PDB Code 
adenosine deaminase 1.0 2AMX; 2PGF; 2PGR; 2QVN 
ribonucleotide reductase small subunit 1.0 2O1Z; 2P1I 
cell division control protein 2 homolog 0.9 1LCH; 1OB3; 1V0B; 1V0O; 1V0P 
casein kinase 1 0.9 1LHX 
glutathione reductase 0.9 1ONF 
NADP-specific glutamate dehydrogenase 0.8 2BMA 
farnesyl pyrophosphate synthase 0.8 2IHI 
adenylosuccinate synthetase 0.8 1P9B 
multidrug resistance protein 2 0.7 2GHI 
deoxyuridine 5'-triphosphate nucleotidohydrolase 0.6 1VYQ 
triosephosphate isomerase 0.8 
1LYX; 1LZO; 1M7O; 1M7P; 1O5X; 
1VGA; 1WOA; 1WOB; 1YDV; 2FI6 
ubiquitin-conjugating enzyme 0.28 2PWQ 
glyceraldehyde-3-phosphate dehydrogenase 0.28 1YWG; 2B4R; 2B4T 
nucleoside diphosphate kinase b 0.2 1XIQ 
small GTPase Rab11 0.2 3BFK 
dimethyladenosine transferase 0.2 2H1R 
phosphoglycerate mutase 0.2 1XQ9 
protein-L-isoaspartate O-methyltransferase beta-aspartate 
methyltransferase 
- 2PBF 
2-Cys peroxiredoxin - 2H01; 2H66; 2I81 
beta-hydroxyacyl-acp dehydratase precursor - 1Z6B; 1ZHG; 2OKH; 2OKI 
fructose-bisphosphate aldolase - 1A5C; 2EPH; 2PC4 
ribosomal RNA methyltransferase - 2PLW 
pyrroline carboxylate reductase - 2RCY 
adenylosuccinate lyase - 2HVG; 2QGA 
P. falciparum 
2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase - 3B6N 
*The druggability index values range from 0 to 1, where a larger index score means a more likely to be druggable target. The druggability index is a composite score consisting of a 
weighted normalised sum, where each of the different druggability prediction methods are given different weights depending on their relative contribution to prediction [58]. 
 
 Experimental and computational structure-based methods 
applied to tropical diseases contribute to shed some light on 
both the understanding the biology of infectious organisms 
and the enabling competence for rational drug design. 
Additionally, the combination of these techniques is 
expected to accelerate the process of hit identification, lead 
optimization and NCE generation. The relevance of this stra-
tegy for the development of novel chemotherapeutic agents 
against tropical diseases is highlighted by several successful 
examples in the following sections. 
TRYPANOSOMIASIS AND SBDD  
 Parasitic infections caused by trypanosomatids represent 
several of the major neglected diseases, including leish-
maniasis, sleeping sickness (human African trypanosomiasis, 
HAT) and Chagas’ disease (American trypanosomiasis). The 
causative agents of these illnesses are Leishmania ssp., 
Trypanosoma brucei ssp. and Trypanosoma cruzi, respec-
tively. They occur in both tropical and subtropical regions 
worldwide and affect about 30 million people with another 
400 million living in high-risk areas [73-75]. All existing 
therapeutic treatments have inadequate efficacy and unac-
ceptable toxicity profiles.  
 Several different classes of compounds were approved 
for the treatment of leishmaniasis (Fig. 1) [19]. Since the 
1940s the basis of antileishmanial chemotherapy consist of 
pentavalent antimonial drugs (e.g., meglumine antimoniate 
and sodium stibogluconate), however, these agents require a 
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Fig. (1). Molecular structure of approved drugs for trypanosomiasis. 
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long course of parenteral administration, and many cases of 
lack of efficacy were reported [19,23]. Amphotericin B has 
been used as an alternative therapeutic option, nonetheless, it 
must also be administered parenterally, and causes serious 
toxic effects (e.g., nephrotoxicity). To circumvent this issue, 
novel formulation approaches such as drug liposome encap-
sulation were developed. This new presentation is much less 
toxic than the standard one, however, it is very expensive to 
be used for routine antileishmanial chemotherapy in the 
developing world. More recently, miltefosine, the first oral 
drug for the treatment of visceral leishmaniasis was regis-
tered. Unfortunately, the drug shows severe gastrointestinal 
side effects and must be given over a long course of treat-
ment [76]. 
 The current therapeutic arsenal for sleeping sickness 
mainly consists of three drugs, which were introduced more 
than half a century ago (suramin, pentamidine and melar-
soprol) and one more recently registered (eflornithine) (Fig. 
1). Suramin and pentamidine are only active in the first stage 
of the disease when the parasites reside in the bloodstream 
and lymphatic system. Alternatively, melarsoprol and eflor-
nithine are used for the treatment of sleeping sickness when 
the parasites have established themselves in the central 
nervous system (late-stage). Unfortunately, a significant 
number of patients with secondary-stage sleeping sickness 
show resistance to melarsoprol, whilst eflornithine is 
ineffective against T. brucei rhodesiense (prevalent in 
eastern and southern African countries) and only used to 
treat the disease caused by T. brucei gambiense (prevalent in 
western African countries) [19,23].  
 One hundred years have passed since the discovery of 
Chagas’ disease [77], however, the only clinically available 
alternatives for the chemotherapy are nifurtimox and benz-
nidazol (Fig. 1). Both compounds have serious side effects 
and are active only in the acute phase of the disease. In 
addition, their usefulness in the intermediate and late chronic 
stage of the infection is highly questionable [78].  
 As stated above, the identification of new macro-
molecular targets and small-molecule modulators is of 
utmost importance for the development of novel and effe-
ctive anti-trypanosomatids agents. Thus, a brief review of the 
recent discoveries based on SBDD approaches for trypano-
somiasis is presented in the following sections. 
Pteridine Reductase Inhibitors 
 Enzymes involved in the provision and use of reduced 
folate cofactors such as dihydrofolate reductase (DHFR, EC 
1.5.1.3) and thymidylate synthase (TS, EC 2.1.1.45) are 
suitable drug targets for the treatment of several diseases 
(e.g, bacterial infections, cancer, and malaria). Inhibition of 
DHFR or TS reduces the cellular pool of 2’-deoxythymidine-
5’-monophosphate, impairing DNA replication and resulting 
in cell death [79,80]. Since trypanosomatids are auxotrophic 
for folates, the inhibition of the enzymes is expected to kill 
the parasites. However, these organisms also have the pteri-
dine reductase enzyme (PTR1, EC 1.5.1.33), essential for 
salvage of pterins by parasitic trypanosomatids that shows a 
broad range of activity catalyzing successive reductions of 
conjugated (folate) and unconjugated (biopterin) pterins. In 
the presence of DHFR-TS inhibitors, PTR1 is overexpressed 
in trypanosomatids leading to sub-optimal concentration of 
the inhibitors to ensure parasite death [81,82]. This 
biological mechanism of resistance suggests that inhibition 
of both DHFR and PTR1 could be useful for the treatment of 
trypanosomatids infections.  
 To confirm this assumption, a database of 440 synthetic 
folate-like compounds was analyzed aiming at identifying 
new inhibitors of both enzymes [83]. A series of physico-
chemical- and pharmacokinetic-based filters was applied to 
the database retrieving 131 molecules that fit the selection 
criteria. The inhibitory activity of the compounds were 
assessed against a panel of folate-dependent enzymes, 
including DHFR/TS from L. major, and PTR1 from L. major 
and T. cruzi. Additionally, inhibition data of DHFR/TS 
human homologues were used to estimate the toxicity and 
selectivity of the compounds. The biological assays 
identified 9 selective and potent compounds against the 
parasite enzymes. Compound (1) was the best inhibitor of 
LmPTR1 and LmDHFR (Ki value of 0.1 M and 4 M, 
respectively) and one of the most selective inhibitors in the 
series (Fig. 2A). Crystallographic assays were undertaken to 
shed light on the molecular mechanism and binding mode of 
the lead compound. The ternary complex LmPTR1–
NADPH-1 analysis revealed that the inhibitor adopts a sub-
strate-like orientation (Fig. 2B). Based on this finding, a 
similarity search was conducted to retrieve new potential 
inhibitors from the library. This procedure identified 4 com-
pounds which were tested against LmPTR1 and human 
DHFR. The best analogue, compound (2), a methylated 
derivative of (1) (Fig. 2A), exhibited Ki values of 0.037 and 
0.820 M against LmPTR1 and human DHFR, respectively. 
Further crystallographic studies revealed that compound (2) 
orientates the methyl group toward a small hydrophobic 
pocket within the catalytic site (Leu226 and Leu229, Fig. 
2B) which favorably contribute to the inhibitory activity.  
 Subsequently, in vitro assays against the whole L. major 
and T. cruzi parasites were carried out. The inhibitors 
showed poor efficacy when tested independently, however, 
when used in combination with known DHFR inhibitors, a 
synergic and deleterious effect to parasites was observed. 
These results indicate that essential biochemical processes 
for parasite viability were targeted and corroborated the pre-
vious assumptions. Furthermore, these findings provide an 
alternative therapeutic approach against trypanosomatids. 
Cruzain inhibitors 
 Cysteine proteases are widespread in nature [84]. Their 
implication in numerous vital processes of several parasitic 
protozoa makes them highly attractive targets for drug 
design [85,86]. Cruzain (EC 3.4.22), the major cysteine 
protease of T. cruzi, plays a pivotal role during the infection 
of host cells, replication, and metabolism, and has been 
extensively investigated as an attractive target for the 
development of a new generation of antitrypanosomal agents 
[87-96]. Indeed, cruzain inhibitors are amongst the most 
advanced compounds in the drug development pipeline for 
Chagas’ disease. For instance, K11777, a dipeptidyl vinyl 
sulfone derivative (Fig. 3), is currently in preclinical trials 
[96,97]. 
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 Aiming at developing nonpeptidic inhibitors of cruzain 
with improved biological activity and pharmacokinetic pro-
perties, an alternative approach based on substrate activity 
screening (SAS) was employed to screen a library of pro-
tease triazole-based substrates [98]. The SAS method con-
sists of three main steps: (i) the identification of nonpeptidic 
substrate; (ii) substrate optimization and (iii) conversion of 
optimal substrates to inhibitors [99]. The first step of the 
procedure identified compounds (3) and (4) as potential hits 
in the focused library (Fig. 3). Subsequently, a series of 
iterative cycles of organic synthesis and biological eva-
luation was carried out to enhance the cleavage efficiency. 
The optimization step was guided by molecular modeling 
based on the structure of a closely related ketone triazole 
analogue in complex with cathepsin S. Significant structural 
differences in the S3 pockets of the enzymes allow the 
design of cruzain-specific substrate incorporating planar 
heterocycles in place of the phenyl ring of the benzamide 
moiety (i.e., cruzain S3 pocket is larger and hydrophobic) 
(Fig. 3). The most promising substrates synthesized were the 
quinoline and benzothiazole derivatives (compounds (5) and 
(6), respectively) with 7–9 fold improvement in cleavage 
efficiency related to compound (3) (Fig. 3). The structure-
based studies also indicated that the benzamide carbonyl of 
the substrate is solvent exposed and therefore, could be 
replaced. Based on this hypothesis, amine and amide deri-
vatives were obtained and assessed. The enzymatic assay 
confirmed the modeling hypothesis and identified the 
quinoline amine (7) and benzothiazole amine derivatives (8) 
as the most potent substrate with cleavage efficiency 19-fold 
greater than the unsubstituted benzamide (3) (Fig. 3). 
 Since potent and promising substrates were obtained, the 
final step of the SAS method was initiated. The strategy to 
convert substrates into cruzain inhibitors was based on the 
replacement of the aminocoumarin group with several 
mechanism-based pharmacophores (e.g., vinyl sulfone (9), -
chloro vinyl sulfone (10), acyloxymethyl ketone (11) and 
aryloxymethyl ketone (12)) (Fig. 3). Time-dependency 
assays revealed that compounds (11) and (12) were authentic 
irreversible inactivators of cruzain with excellent inhibitory 
acitvity [98]. Then, cell culture assays were employed to 
evaluate the inhibitors effectiveness in eliminating T. cruzi 
infection. On one hand, the experiment revealed that 
compound (11) significantly delayed T. cruzi intracellular 
replication at 5 μM (trypanostatic agent), however, it showed 
toxic effects at this concentration. On the other hand, 
compound (12) was trypanocidal at 10 μM and had comp-
letely eradicated the T. cruzi parasite from the infected cells 
[98]. The biological properties of (12) are similar to the most 
advanced cruzain inhibitor (K11777, 100% inhibition of 
intracellular growth of T. cruzi amastigotes at 20 M; oral 
bioavailability ~ 20%) [95,97], suggesting that this molecule 
is a potential lead compound for the development of a new 
generation of nonpeptidic inhibitors as antitrypanosomal 
agents [98].  
Phosphofructokinase and Pyruvate Kinase Inhibitors 
 The glycolytic pathway of trypanosomatids has been 
investigated as a promising biochemical target for drug inter-
vention [27]. The bloodstream form of trypanosomatids has 
no functional tricarboxylic acid cycle and is highly depen-
dent on glycolysis for ATP production [100,101]. Addi-
tionally, the parasite enzymes within the pathway possess 
significant structural differences with respect to the human 
homologues. Therefore, the vital dependence on glycolysis 
as the main source of energy for the parasites, combined to 
distinct molecular properties when compared with their 
human counterparts makes the glycolytic enzymes attractive 
targets for drug design. Structure- and ligand-based approa- 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). (A) Molecular structures and biological activity of the best PRT1 inhibitors. (B) Binding mode of (2) to PTR1 binding site (PDB ID, 
2QHX). The protein is indicated as cartoon and the binding site residues as ball-and-stick model. The ligand and cofactor molecules are 
represented as stick model and hydrogen-bond as broken lines. 
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Fig. (3). Substrate activity screening (SAS) approach and molecular structure of the most promising compounds identified in each step. Insert, 
predicted binding mode of a ketone triazole analogue (orange) within cruzain binding site (PDB ID, 1F2C). The protein Connolly surface is 
indicated with protein atoms colored according to the physicochemical property (hydrophobic atom in pale yellow; positively charged atom in 
blue; negatively charge atom in red, polar nitrogen atom in light blue, polar oxygen atom in light red, and sulfur atom in yellow). 
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Fig. (4). Upper panel. Crystallographic structures of PFK (PDB ID, 2HIG) and PyK (PDB ID, 1PKL). Lower panel. Molecular structure and 
related biological properties.  
 
ches on enzymes of the carbohydrate metabolism pathway 
have identified several promising inhibitors, as well as shed 
light on the structural basis for selective inhibition [102-
117].  
 Phosphofructokinase (PFK, EC 2.7.1.11) and pyruvate 
kinase (PyK, EC 2.7.1.40) (Fig. 4) play important role in 
trypanosomatids glycolytic flux and were explored as mole-
cular target for the development of trypanocidal agents 
[118]. Previously, pioneering kinetic and inhibition studies 
conducted on T. brucei PFK (TbPFK) substrate analogues 
have identified a nonphosphorylated mannitol derivative 
((13), IC50 = 1,100 M) as an interesting starting point for 
inhibitor design [119] (Fig. 4). Due to the structural 
similarities between fructose 6-phosphate (F6P) and fructose 
2,6-bisphosphate (F2,6BP), respectively substrate and 
allosteric regulators of PFK and PyK, L. mexicana PyK 
(LmPyK) was also included in the inhibition assays. 
 Aiming at exploring the SAR within this series, a focused 
library of amine derivatives of (13) was synthesized and 
evaluated against TbPFK and LmPyK. On one hand, 
compound (14), bearing a 3,4-dichlorobenzyl substituent, 
was the most potent inhibitor against TbPFK (IC50 = 410 
M). On the other hand, compound (15), a cycloheptyl 
mannitol derivative, exhibited good inhibitory activity 
against LmPyK (IC50 = 71 M) (Fig. 4). These findings 
prompted further investigation on the inhibitor scaffold that 
explored the chemical diversity of mannonamide derivatives. 
Significant improvements in potency against TbPFK was 
observed when the 3,4-dichlorobenzamide substituent was 
obtained ((16), IC50 = 23 M). Similarly, the addition of a 
cycloheptyl-amide moiety to (15) led to some enhancement 
in the inhibitory activity against LmPyK ((17), LmPyK IC50 
= 26 M) (Fig. 4).  
 Molecular docking studies were undertaken with both 
enzymes to elucidate the structural determinants underlying 
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the biological properties within this series. Regarding 
TbPFK, the model indicated that the increase in potency 
observed for (16) could be explained by hydrogen-bonds and 
hydrophobic interactions between the 3,4-dichlorobenzamide 
substituent and the aminoacid residues within active site. 
Comparable results were obtained when (17) had been 
modeled within LmPyK binding pocket. The enhanced 
potency might be due to the increase in hydrophobic bulk. 
Therefore, the molecular models correlate well with SAR 
data and provide a reasonable explanation for the observed 
biological activities. 
 Since in vitro activity evidences are desirable to help 
with subsequent lead identification and modification, 
inhibitory evaluation against the whole parasite was carried 
out to confirm the biological activity of the designed 
inhibitors. The biological assay against T. brucei revealed 
that the inhibitors exhibit some modest activity against the 
cultured parasite (compound (16) was the most potent 
inhibitor with ED50 value of 30 M) [118].  
 In summary, this work highlights the first steps in drug 
design for parasitic diseases which involved (i) the optimi-
zation of a series of previously identified inhibitor; (ii) 
structural insights into the inhibitor binding mode through 
molecular modeling studies and (iii) preliminary in vivo 
activity evaluation.  
MALARIA AND SBBD  
 Malaria is spread over 90 countries worldwide and is 
responsible for approximately 300 million acute cases each 
year, with 1.5 to 2.0 million fatalities. Nearly 90% of the 
deaths occur in sub-Saharan African regions. The protozoan 
Plasmodium falciparum is the etiological agent of the most 
severe and life-threatening form of disease [120]. 
 The emergence of resistance to the current most afford-
able drugs, such as chloroquine, mefloquine and sulfado-
xine-pyrimethamine (Fig. 5), represents a major problem for 
malaria control. Accordingly, many countries must consider 
alternative approaches to slow the development of resistance, 
for instance, artemisinins analogues or drug combinations 
(e.g., atovaquone-proguanil, amodiaquine-artesunate). Fig. 
(5) shows the molecular structures of the current available 
drugs for malaria. However, these therapeutical choices 
show serious cost limitations for patients from developing 
countries, particularly in Africa. Moreover, various anti-
malarial drugs in current usage are chemically related or 
show similar mode of action, possibly sharing resistance 
mechanisms, which increases the risk of cross-resistance and 
clinical failure of newly introduced therapies [121].  
 The continuously increasing resistance of the vector 
toward insecticides as well as the emergence of multidrug-
resistant parasites greatly necessitates the development of 
new anti-infective agents that have either a novel binding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Molecular structure of approved drugs for malaria. Combinations of theses drugs potentially offer a number of important advantages 
over monotherapies (e.g., sulfadoxine-pyrimethamine; atovaquone-proguanil; artesunate-mefloquine; amodiaquine-artesunate; mefloquine-
artesunate; chlorproguanil-dapsone-artesunate and lumefantrine-artemether). 
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mode or a new mechanism of action, which is pivotal to 
combat the most pernicious form of human malaria. Some 
recent advances toward this goal are presented in the 
following sections. 
Farnesyltransferase inhibitors 
 Farnesyltransferase (PFT, EC 2.5.1.21) catalyzes the 
transfer of the 15-carbon farnesyl group from farnesyl 
pyrophosphate (FPP) to the cysteine residue in the C-
terminal motif CAAX (where C: cysteine, A: aliphatic amino 
acid, X: serine or methionine). The enzyme is involved in 
several intracellular signal transduction events and has been 
extensively investigated for the development of novel 
anticancer agents [122-124]. PFTs were also identified in 
other eukaryotic organisms including the pathogenic 
protozoa parasites [125-128]. Hence, inhibition of PFT was 
suggested as an alternative strategy for the treatment of 
parasitic infections. Previously, studies on PFT inhibitors 
have identified and developed compounds with enhanced 
medicinal chemistry and pharmacokinetics properties [38]. 
In this context, there has been considerable research into the 
possible antimalarial activity of drugs designed for other 
diseases (i.e., piggy-back approach) [129-133]. 
 Aiming at discovering innovative non-thiol farnesyl-
transferase inhibitors, a ligand-based pharmacophore model 
was employed to retrieve compounds with the desirable 
features [134]. Peptidomimetic compounds with a benzo-
phenone core were identified as promising lead compounds. 
Subsequently, several cycles of lead optimization led to 
development of compounds with enhanced inhibitory 
potency capable of suppressing the growth of the multiresis-
tant P. falciparum in the nanomolar range [135-139]. 
However, when tested against a murine malaria model the 
inhibitors were inactive. The lack of in vivo activity was 
speculated to be related to the solubility of the compounds. 
Therefore, new cycles of organic synthesis were performed 
to generate benzophenone derivatives with charged groups 
[140].  
 Nitrogen-containing heterocycles substituents were 
selected to be replaced into the -position of the phenyl-
acetamide moiety of the lead compound (18). This strategy 
remarkably increased the inhibitor’ water solubility (from 
<0.06 mM for phenylacetamide derivative (18) to >3.33 mM 
for the piperazine analogue (19)) (Fig. 6). Based on its high 
activity and relative structural simplicity, the inhibitor (19) 
was selected as the new lead compound for further 
optimization. Previously, investigation on benzophenone 
derivatives has identified chlorine as an attractive substituent 
to improve potency [137], thereby, the same approach was 
carried out yielding compound (20) with slightly enhanced 
potency with respect to the parent compound (19) (Fig. 6). In 
order to gain further insights into the structural determinants 
of the binding potency underlying this series, molecular 
docking and homology model studies were undertaken. The 
model indicated that the chlorine substituent in (20) was 
orientated into a binding pocket close to the side chain of the 
His149. Steric hindrance between the piperazinyl moiety and 
some amino acid side chains of the active site might prevent 
the chlorophenyl substituent to adopt the optimal 
conformation to bind to the pocket, thereby reducing the 
interaction between the chlorine and the side chain of the His 
residue [140]. In light of this, two approaches were carried 
out: (i) introduction of a methylene group between the -
position and the phenyl moiety (com-pound (21), aiming at 
improving the interaction between the chlorine substituent 
and the side chain imidazole group; and (ii) replacement of 
the piperazinyl moiety by an open chain ethylenediamine 
substituent (compounds (22) and (23)), the enhanced 
flexibility of this substituent would allow for both an optimal 
chlorine–imidazole interaction as well as for an interaction 
of the terminal amine with the amino acids in the upper part 
of the binding site.  
 The inhibitory activity assays revealed that although 
compound (21) was virtually equipotent against blood stages 
of P. falciparum, it was approximately 30-fold less potent 
than (20) in farnesyltransferase inhibition assays (Fig. 6). On 
the other hand, the ethylenediamine derivatives (22) and (23) 
displayed considerably improved in vitro activity with IC50 
values of 32 and 30 nM, respectively, approximately 7-fold 
more active than inhibitor (20) (Fig. 6). In addition, the 
toxicity profiles of these compounds were assessed against 
cultured parasites in comparison with a human cell line. The 
inhibitors displayed significant selectivity towards malaria 
parasites as well as lack of toxicity of therapeutic doses in 
mice [140]. Accordingly, this is an important contribution 
for the development of specific antimalarial farnesyltrans-
ferase inhibitors. 
Enoyl–acyl Carrier Protein Reductase Inhibitors 
 Fatty acids play a pivotal role in providing metabolic pre-
cursors of biological membranes and represent an important 
alternative source of energy supply [141]. Inhibition of the 
fatty acid biosynthesis pathway has been considered an 
attractive target for drug development [142,143]. Fatty acid 
biosynthesis is an iterative process beginning with the 
condensation of acetyl CoA with the growing fatty acid 
chain. In P. falciparum the enoyl-acyl carrier protein reduc-
tase (PfENR, EC 1.3.1.9) is responsible for the final 
enzymatic step in the elongation cycle: converting trans-2-
enoyl-ACP to acyl-ACP in a NADH-dependent reaction 
[141,142]. The widely used antibiotic triclosan is a potent 
inhibitor of PfENR and Plasmodium growth both in vitro 
and in vivo [144]. Several efforts have been made to 
optimized the PfENR inhibitory potency of triclosan, how-
ever, only modest inhibitors were developed (micromolar 
range) [143,145].  
 With the goal of discovering novel scaffolds with 
promising antiplasmodial activity, a structure-based virtual 
screening approach was carried out with the X-ray of PfENR 
in complex with triclosan [146]. The ICM molecular docking 
program [147] was used to screen a drug-like enriched 
database of 336,600 compounds from the ChemBridge 
Express Library (San Diego, CA) against the crystal-
lographic structure of PfENR (PDB ID, 1NGH). The virtual 
screening protocol consisted of several hierarchical steps 
including (i) theoretical measurements of energy interaction; 
(ii) similarity index; and (iii) ADME-Tox (absorption, distri-
bution, metabolism, excretion, and toxicity) properties 
prediction (Fig. 7A). In the first selection step, putative 
ligands that exhibited ICM scoring better than the cutoff 
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value of -50 were selected (triclosan was employed as a 
benchmark for hit scoring, yielding a score of -40). 
Subsequently, a similarity cluster analysis was applied in 
order to reduce the redundancy as well as increasing the 
molecular diversity. Thus, similar compounds were 
eliminated reducing the initial database to 750 entries. In a 
final filtering step, the selected compounds were subjected to 
a theoretical measure of ADME-Tox features to remove 
compounds with predicted poor pharmacokinetic properties. 
The remaining 169 candidate molecules were acquired and 
biologically evaluated. The experimental screening assay 
against the PfENR identified 16 hits that showed >45% 
inhibitory activity at 50 M. Those compounds were tested 
in cell-based experiments with two P. falciparum strains 
(e.g., Dd2 and 3D7). Three of them exhibited cell growth 
inhibition in the micromolar range, the best inhibitor (24) 
exhibited IC50 values of 6 M and 5 M (Dd2 and 3D7 
strain, respectively) (Fig. 7B) [146].  
 This study was the first virtual screening strategy that has 
been applied to a malarial target. The identified compounds 
represent new leads, potentially suited for oral bioavaila-
bility, with inhibitory potency similar to triclosan. Sub-
sequent optimization processes aimed at optimal subs-
titutions with suitable chemical groups should be useful for 
the design of new structurally related PfENR inhibitors with 
improved in vivo potency as well as ADME properties. 
OTHER RELEVANT TROPICAL DISEASES AND 
SBDD  
 Drug discovery programs for other relevant tropical 
diseases such as schistosomiasis, dengue, and onchocerciasis 
are not worldwide extended or advanced as the research on 
the diseases reviewed so far. Those diseases also represent 
an enormous burden on developing countries, further aggra-
vated by the limited number of available drugs, mechanisms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Benzophenone derivatives developed as potent inhibitor of P. falciparum farnesyltransferase. The P. falciparum Dd2 strain 
(Pf_Dd2) is resistant to several commonly used antimalarial drugs (chloroquine, cycloguanil, and pyrimethamine). 
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of drug action poorly understood, and lack of efficacy of the 
therapeutical regimens. Hence, aiming at delivering new 
drug candidates for the treatment of these illnesses, some 
progress has been made in the identification of novel lead 
compounds.  
 For instance, the enzyme purine nucleoside phos-
phorylase (SmPNP, EC 2.4.2.1) from Schistosoma mansoni, 
the causative agent of schistosomiasis, was selected as a 
molecular target for the identification and kinetic charac-
terization, including potency, affinity and mechanism of 
action, of new inhibitors [148]. The 9-deazaguanines 
derivatives were identified as competitive SmPNP inhibitors 
that exhibited significant inhibitory and selective properties 
(the best inhibitor (27) showed Ki value in the low nano-
molar range) (Fig. 8A). Two of those inhibitors were co-
crystallized with SmPNP, providing important insights on the 
intermolecular interactions responsible for affinity as well as 
gathering structural information useful for medicinal 
chemistry efforts in the design of new inhibitors with 
increased biological properties. Regarding dengue, the 
enzyme methyltransferase (EC 2.7.7.48) from the Flavivirus 
was explored as a molecular target for a computational and 
experimental approach involving (i) pharmacophore search; 
(ii) structure-based virtual screening; and (iii) experimental 
testing. The strategy identified a novel scaffold, the 
adamantane derivative (28), with IC50 value of 60 M (Fig. 
8B) [149]. Concerning onchocerciasis, which is the world’s 
second leading infectious cause of blindness and caused by 
the filarial worm Onchocerca volvulus, the structure-based 
development is very limited. There is only one crystal 
structure with a bound inhibitor for application of structure-
based methods (Fig. 8C). The crystallographic data of the 
major cytosolic glutathione S-transferase (GST, EC 2.5.1.18) 
in complex with the competitive inhibitor S-hexylglutathione 
provided structural insights on the substrate specificities and 
highlighted chemical features of the binding site that can be 
explored for the discovery and design of novel anti-filarial 
compounds [150]. 
CONCLUSION 
 In medicinal chemistry and drug design programs, the 
combination of innovative strategies based structural data 
plays a central role on our increasing understanding of the 
fundamental principles of protein-ligand interactions. Thus, 
besides providing invaluable information about the spatial 
arrangements of the target receptor, SBDD methods allow 
the investigation of intermolecular interactions underlying 
molecular recognition mechanisms and biological activity. In 
this scenario, the integration of experimental and compu-
        B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). (A) The protocol of consecutive steps applied in the virtual screening approach for novel inhibitors of PfENR. (B) Lead compounds 
identified by virtual screening. 
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tational approaches is an important component of modern 
drug discovery campaigns that possess the potential to boost 
the early phases of drug research, particularly in terms of 
time and cost savings. This is the major motivation for the 
partnerships between the public and private sectors which 
have remarkably promoted the drug research programs for 
several tropical diseases. They are stimulating the identi-
fication of promising hits, the generation of high quality 
leads as well as encouraging the successes of moving drug 
candidates into clinical trials. 
 In summary, SBBD methods have a great impact on the 
discovery of new lead compounds for several parasite 
infections. Very promising enzyme inhibitors were identified 
and optimized based on iterative cycles of structure-based 
approaches including biological testing, structure eluci-
dation, computer-aided drug design and synthesis. These 
molecules represent new drug candidates with potent in vitro 
and in vivo activity as well as some improved pharma-
cokinetic properties. Therefore, the next step in this research 
activity aims to progress the drug candidates into the 
development phase.  
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